Induction Phase + Re-Induction Phase + Post-Remission + Maintenance

Phase 2Recruiting

0 views this week 0 watching⚡ Active

Interest: 42/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Conditions

Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia, CD19+ Acute Leukemia

Trial Timeline

May 15, 2026 → Jul 1, 2033

NCT ID

NCT06773936

About Induction Phase + Re-Induction Phase + Post-Remission + Maintenance

Induction Phase + Re-Induction Phase + Post-Remission + Maintenance is a phase 2 stage product being developed by Novartis for Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06773936. Target conditions include Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia, CD19+ Acute Leukemia.

What happened to similar drugs?

2 of 8 similar drugs in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia were approved

Approved (2) Terminated (1) Active (5)

✅NilotinibNovartisApproved

✅AsciminibNovartisApproved

❌NilotinibNovartisPhase 3

🔄NilotinibNovartisPhase 3

🔄Asciminib + NilotinibNovartisPhase 3

🔄Imatinib + Nilotinib + Bosutinib + Dasatinib + AsciminibNovartisPhase 3

🔄Blinatumomab + Blinatumomab + HyperCVADAmgenPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06773936	Phase 2	Recruiting	May 15, 2026	Jul 1, 2033	Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Competing Products

20 competing products in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

See all competitors

Product	Company	Stage	Hype Score
Imatinib Mesylate	Novartis	Phase 2	35
Nilotinib	Novartis	Phase 3	32
Nilotinib	Novartis	Phase 3	40
STI571 400 mg + STI571 600 mg	Novartis	Phase 2	35
nilotinib	Novartis	Phase 2	35
Asciminib + Nilotinib	Novartis	Phase 3	44
imatinib mesylate	Novartis	Phase 2	35
Blinatumomab + Asciminib	Novartis	Phase 1/2	39
Asciminib	Novartis	Phase 1	36
Asciminib Pediatric formulation group + Asciminib Adult formulation group	Novartis	Phase 1/2	39
Nilotinib + LDE225	Novartis	Phase 1	29
Nilotinib	Novartis	Approved	43
Imatinib + Nilotinib + Bosutinib + Dasatinib + Asciminib	Novartis	Phase 3	44
Asciminib	Novartis	Approved	47
Blinatumomab	Amgen	Phase 2	35
Treatment with blinatumomab given subcutaneously.	Amgen	Phase 2	42
Blinatumomab + Blinatumomab + HyperCVAD	Amgen	Phase 3	47
Blinatumomab + Low-intensity chemotherapy regimen + SOC chemotherapy regimen	Amgen	Phase 3	47
Bosutinib	Pfizer	Phase 1/2	36
Bosutinib + Bosutinib	Pfizer	Phase 1	29